Project Grant W81XWH2210516
Award Date
7/1/22
Completion Date
6/30/26
Dollars Obligated
$10M
Federal Agency
Medical Command
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55435, USA
Similar Awards
The Massachusetts General Hospital will receive $826,584 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research into the mechanisms mediating the immune response after proton versus photon radiotherapy in IDH-mutant liver cancer. The study aims to investigate medical solutions for the battlefield and transform health care for service members and the public through innovative...
The Department of the Army Medical Command awarded a $157,500 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2021 to May 31, 2022 to restore functional ARF tumor suppression in non-small cell lung carcinoma through the use of peptide mimics. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...
The federal Project Grant award of $1,851,874.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public, with a particular emphasis on conditions relevant to military personnel and veterans. The primary awardee, The Henry M. Jackson Foundation for the Advancement of Military Medicine,...
This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass...
This $305,917 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of an off-the-shelf reparative T regulatory cell (Treg) immunotherapy to limit tissue damage and initiate effective repair and resolution after lung injuries. The University of Pittsburgh, a major research institution, is the prime awardee on this 2-year grant with a performance period from December 1, 2023 to November 30,...
The Defense Health Agency awarded a $168,000 Project Grant to the Massachusetts General Hospital, a division of Partners Healthcare System Incorporated, to support research on carbonizing proton beam therapy for lung cancer. The grant was awarded on January 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) to transform health care for service members and the public through innovative medical research solutions for battlefield injuries and investigations into...
The Department of the Army Medical Command awarded a $202,800 Military Medical Research and Development (CFDA 12.420) project grant to the Icahn School of Medicine at Mount Sinai to conduct research on "Spatial Copy Number and Morphologic Alterations in Early Lung Carcinogenesis." The award, with a performance period from September 30, 2025 to September 29, 2026, will support advanced biomedical research focused on transforming healthcare for military service members and the public....
The Department of the Army Medical Command awarded Duke University a $547,664 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2021 to May 2023 to exploit targeted therapy-induced ATM dependence in residual lung tumors. Through this award, Duke University researchers will investigate medical solutions for the battlefield by transforming health care for Service Members and the American public through innovative and...
This $159,900 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports preclinical research on brain metastases in lung cancer. The award will fund studies at the University of Illinois to develop and evaluate novel drug efficacy and resistance models for advancing the treatment of brain metastases, a significant challenge in lung cancer management. Spanning one year from August 2024 to August...